BIOTECH: TANDEM MAY GAIN PATIENTS WHILE DEXCOM MIGHT LOSE USERS
J&J’s Exit From Insulin Pump Market to Affect Tandem, DexCom
Originally published October 12, 2017 at 2:08 p.m., updated October 12, 2017 at 2:08 p.m.
San Diego — Johnson & Johnson’s announcement that it will exit the insulin pump businesses appears to benefit one San Diego company, Tandem Diabetes Care, and potentially hurt another, DexCom...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know